Press Releases

Cleerly is aware of the lawsuit filed by Heartflow. We are confident in our extensive and well-established intellectual property portfolio and the originality of our technology.

Cleerly has published landmark clinical science that has redefined how cardiovascular disease is understood and treated, which has formed the basis of our novel technologies that provide physicians with actionable insights into their patients’ heart health.

Cleerly was founded on a mission to create a world without heart attacks, and we have never been more focused in our mission and committed to the patients and physicians who count on us.

For any questions, please reach out to press@cleerlyhealth.com

Cleerly and Allelica Partner to Launch a Polygenic Risk Score Test for Coronary Artery Disease

July 30, 2026

The Cleerly Polygenic Cardiovascular Risk Score Test, powered by Allelica’s proprietary multi-ancestry PRS technology, gives physicians a new option...

Cleerly to Debut Customizable Full Text Reports and Present New AI-QCT Research at SCCT2026

July 7, 2026

New Full Text Report Configurability and Six Scientific Presentations at the 21st Annual Scientific Meeting of the Society of Cardiovascular Computed...

MemorialCare Heart & Vascular Institute Becomes First Hospital in Los Angeles County to Offer Cleerly AI-Powered Heart Disease Analysis, Quantifying Total Plaque Volume and Soft Plaque

May 20, 2026

Systemwide launch brings AI powered assessment to Coronary CTA’s to MemorialCare’s Long Beach Medical Center, Orange Coast Medical Center, and...

Cleerly's Statement on Heartflow’s lawsuit to limit competition

April 17, 2026

At Cleerly, our mission has always been clear and unwavering: to create a world without heart attacks. Every decision we make – from the innovative...